Radiance to start RAPID (Radiation After PTA is Done) RDX trial:
This article was originally published in Clinica
Executive Summary
Radiance Medical Systems is to begin a clinical trial in the US to assess its RDX radiation delivery system as a means of preventing restenosis in the peripheral vasculature. The RAPID (Radiation After PTA is Done) trial is part of an international study, already underway in Europe, designed to enrol up to 50 patients. The RDX system will be used to treat the superficial femoral artery, popliteal arteries and the primary arteries of the middle and lower leg. The study will include both de novo and in-stent lesion, says the Irvine, California firm.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.